The Pattern of Attrition from an Antiretroviral Treatment Program in Nigeria

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Odafe, Solomon ^a   Torpey, Kwasi ^a   Khamofu, Hadiza ^a   Ogbanufe, Obinna ^a   Oladele, Edward A ^a   Kuti, Oluwatosin ^a   Adedokun, Oluwasanmi ^b   Badru, Titilope ^b   Okechukwu, Emeka ^c   Chabikuli, Otto ^d,e  

^a Prevention Care and Treatment Department   (Nigeria)

^b Monitoring and Evaluation Department   (Nigeria)

^c HIV/AIDS/TB Unit USAID Nigeria   (Nigeria)

^d SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^e Southern Africa Region   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ATTITUDE TO HEALTH; ATTRITION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NIGERIA; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY HEALTH CARE; SEX DIFFERENCE; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HOSPITALS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NIGERIA; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STAVUDINE; TIME FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 84871260842     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051254     Document Type: Article

References (41)

1. WHO, UNAIDS, UNICEF (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Treatment and care for people living with HIV. pp. 4.
2. Chi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, et al. (2011) Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 8: e1001111.
3. Rosen S, Fox MP, Gill CJ, (2007) Patient Retention in Antiretroviral Therapy programs in sub-Saharan Africa: A systematic review. PLoS Med 4: e298.
4. Tayler-Smith K, Zachariah R, Manzi M, Kizito W, Vandenbulcke A, et al. (2011) Antiretroviral treatment uptake and attrition among HIV-positive patients with tuberculosis in Kibera, Kenya. Tropical Medicine and International Health 16.
5. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-1-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin World Health Organization 86: 559-567.
6. Dahab M, Charalambous S, Hamilton R, Fielding K, Kielmann K, et al. (2008) That is why I stopped the ART″: Patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health 8.
7. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, et al. (2007) Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19: 658-665.
8. Unge C, Johansson A, Zachariah R, Some D, Van Engelgem I, et al. (2008) Reasons for unsatisfactory acceptance of antiretroviral treatment in the urban Kibera slum, Kenya. AIDS Care 20: 146-149.
9. UNAIDS (2009) HIV and AIDS Estimates (Nigeria). Geneva: UNAIDS.
10. National Agency for the Control of AIDS (NACA) (2007) Nigeria UNGASS Report. In: Strategic planning and research, editor. Abuja: NACA. pp. 20.
11. UNAIDS (2009) Epidemiological factsheet. Nigeria. Geneva: UNAIDS.
12. National agency for the control of AIDS (NACA) (2010) National HIV/AIDS Strategic Plan (2010-2015). In: Policy and Strategy, editor. Abuja: NACA. pp. 82.
13. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895.
14. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19: 2141-2148.
15. Van Damme W, Kober K, Laga M, (2006) The real challenges for scaling up ART in sub-Saharan Africa. AIDS 20: 653-656.
16. Odafe S, Idoko O, Badru T, Aiyenigba B, Suzuki C, et al. (2012) Patients' demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. Journal of the International AIDS Society 15.
17. Federal Ministry of Health (FMoH) (2004) Revised National Health Policy. In: Health Planning Research and Statistics, editor. Abuja: FMoH.
18. Federal Ministry of Health (FMOH) (2007) National guidelines for HIV and AIDS treatment and care in adolescence and adults. In: National AIDS/STI Control Programme (NASCP), editor. Introduction. Abuja Nigeria: FMOH. pp. 12.
19. Federal Ministry of Health (FMoH) (2007) National guidelines for Paediatric HIV and AIDS Treatment and Care. In: HIV/AIDS Division, editor. Abuja: FMoH. pp. 116 to 120.
20. Federal Ministry of Health (FMoH) (2007) National guidelines for HIV and AIDS treatment and care in adolescents and adults. In: National AIDS/STD Control Programme, editor. Abuja: FMoH. pp. 32.
21. World Health Organization (WHO) (2006) Patient Monitoring Guidelines for HIV Care and Antiretroviral Therapy (ART). In: HIV/AIDS, editor. Geneva: WHO Press. pp. 30-31.
22. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, et al. (2011) Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One 6: e18453.
23. Minga A, Lewden C, Dohoun L, Abo Y, Emieme A, et al. (2010) Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Cote d'Ivoire. AIDS Res Hum Retroviruses 26: 991-995.
24. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y, (2011) Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr 56: 59-63.
25. Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, et al. (2010) A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/muL in South Africa. J Infect Dis 202: 1529-1537.
26. Mateo MG, Gutierrez Mdel M, Vidal F, Domingo P, (2012) Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. Expert Opin Drug Saf 11: 473-485.
27. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, et al. (2010) Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 54: 63-70.
28. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, et al. (2010) Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One 5: e10584.
29. Morillo Verdugo R, Gil Navarro MV, Abdel-Kader Martin L, Castillo Munoz A, Banos Roldan U, et al. (2007) [Analysis of the causes and predictive factors for discontinuing treatment with tenofovir in pretreated HIV patients]. Farm Hosp 31: 200-205.
30. Brennan A, Evans D, Maskew M, Naicker S, Ive P, et al. (2011) Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 25: 1603-1609.
31. Braitsein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:comparison between low-income and high-income countries. The Lancet 367: 817-824.
32. Lawn SD, Myer L, Harling F, Orrell C, Bekker L-G, et al. (2006) Determinants of mortality and non death losses from an antiretroviral treatment service in South Africa:implications for program evaluation. Clin Infect Dis 43: 770-776.
33. Wandeler G, Keiser O, Pfeiffer K, Pestilli S, Fritz C, et al. (2012) Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr 59: e9-16.
34. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, et al. (2008) Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 13: 513-519.
35. Dalal RP, Macphail C, Mqhayi M, Wing JFC, Chersich MF, et al. (2008) Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 47: 101-107.
36. Brinkhof MWG, Boulle A, Weigel R, Messou E, Mathers C, et al. (2009) Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with H{[pipe}IV-unrelated mortality. PLoS Med 6.
37. Brinkhof MWG, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-1-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin World Health Organization 86: 559-567.
38. Boille A, Bock P, Osler M, Cohen K, Channing L, et al. (2008) Antiretroviral therapy and early mortality in South Africa. Bulletin World Health Organization 86: 678-687.
39. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.
40. O'Brien DP, Sauvageot D, Zachariah R, Humblet P, (2006) Medecins Sans Frontiieres (2006) In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 20: 1955-1960.
41. Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, et al. (2006) Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 20: 2315-2319.